

ESCCA 2024

Preliminary programme (subject to change)

WEDNESDAY 25 SEPTEMBER 2024

PRE-CONFERENCE WORKSHOPS

09:00-12:30	WS01	Workshop 1: MRD in ALL	Eivissa 1
		Organisers: Ester Mejstrikova (Prague, CZ) and Michaela Reiterová (Prague, CZ)	
		Level: Intermediate/Advanced. Max. 20 places, pre-registration required	
		MRD in ALL is essential tool in monitoring treatment efficacy. Despite its frequent use in	n the majority of modern
		treatment protocols several issues remains unresolved and questionable. In BCP ALL re	generation of hematogones
		hampers sensitivity and interpretation might be subjective. Targeted treatment anti-19	
		influences regeneration of normal B cell precursors. Newly defined subsets of BCP ALL i	
		rearrangement frequently undergo lineage switch towards mnocytic lineage and B cell switched blasts. In T ALL we will discuss the role of immunophneptypic heterogeneity in	
		Category of immature T ALLs ("early T cell precursor leukemia") is frequently characteri	
		TCR genes resulting in unavailability of MRD assessment by molecular techniques and f	
		subset. During the workshop we will analyze FCS files of B and T ALL MRD samples.	
09:00-09:45		MRD in BCP ALL introduction	Ester Mejstrikova
09:45-10:30		MRD in BCP ALL practical part	Ester Mejstrikova,
			Michaela Reiterova
10:30-11:00		Coffee break	
11:00-11:45		MRD in T ALL introduction	Michaela Reiterová
11:45-12:30		MRD in T ALL practical part	Michaela Reiterová,
			Ester Mejstrikova
09:00-12:30	WS02	Workshop 2: Extracellular vesicles: welcome to the nano-flow world	Eivissa 2
		Organiser: Alfonso Blanco (Dublin, IE)	
		Level: Intermediate/Advanced. Max. 20 places, pre-registration required	
		During this workshop, we will explain the technological difficulties of working with extr sample collection, storage and preparation and how they can influence in the final resu technical considerations for the analysis of the EVs as well as what are the best practice instruments for this analysis. A practical session will take place showing how to perform analysis and how to detect some issues such as swarming effect. The programme will follow soon.	Its. We will also cover the es to optimize samples and
09:00-12:30	WS03	Workshop 3: A practical approach to Immunodeficiency Analysis	Eivissa 3
		Organiser: Fariba Tahami (London, UK) and Martín Pérez-Andrés (Salamanca, ES)	
		Level: Intermediate. Max. 20 places, pre-registration required	
		The participants will be trained in the following topics: i) screening of immunodeficience cytometry including: severe and non-severe combined immunodeficiencies, predomina disease of immune dysregulation, ii) flow cytometry predictors of complication and sho functional test for validation of monogenic immunodeficiencies.	antly antibody deficiencies, and
09:00-9:30		Diagnostic screening and classificacion of PID using flow cytometry	Martin Perez-Andres
9:30-10:15		Screening of PID by FCM: Live case orientation	Martin Perez-Andres
10:15-10:45		Pathogenic classificacion of CVID patients using FCM	Martin Perez-Andres
10:45-11:00		Coffee break	
11:00-12:30		Functional tests for validation of monogenic immunodeficiencies	Fariba Tahami

09:00-12:30	WS04	Workshop 4: Panel design and optimisation in standard and spectral flow-cytometry	Eivissa 4
		Organiser: Cristina Teodosio (Salamanca, ES) and Julio Pozo (Salamanca, ES) Level: Intermediate. Max. 20 places, pre-registration required	
		Flow cytometry has grown exponentially in the last decade, with the introduction of inst (>20) fluorescent parameters simultaneously, the development of spectral flow cytome (new) fluorochromes. While these developments have allowed for new applications and effective panel design has become increasingly more complex. During this workshop, we will discuss the technical advances and differences in convent and how to address the panel design for the different platforms. We will also cover stra data troubleshooting and have a guided panel design practical session.	try, and the increasing number of d more flexibility, the process of cional and spectral flow cytometry,
09:00 - 09:45		Conventional vs. spectral flow cytometry: principles and technical advances	Cristina Teodosio
09:45 - 10:30		Principles and good practices for panel design in flow cytometry	Cristina Teodosio
10:30-11:00		Coffee break	
11:00 - 11:30		Assay optimisation and data troubleshooting	Julio Pozo
11:30 - 12:30		Practical panel design exercise for conventional and spectral instruments	Cristina Teodosio/Julio Pozo

CONFERENCE PROGRAMME

14:00-15:00	PLE01	Opening & Keynote Lecture 1	Auditorium Mallorca
14:00-14:15 14:15-15:00	PLE01-01	Welcome address by the ESCCA President & Announcements Keynote Lecture: Phenotype of Innate Myeloid Cells	Francesco Buccisano (Rome, IT) Christina Teodosio (Salamanca, ES)
15:00-15:30	IPP01	ESCCA Industrial Partner Presentation 1	
15:30-16:00		Coffee break	Exhibition area
16:00-17:00	PLE02	ESCCA-ICCS joint session Challenging lineage definition in Acute Leukemia	Auditorium Mallorca
16:00-16:30	PLE02-01	Mixed phenotype/mixed lineage acute leukemia	Sindhu Cherian (Washington, USA)
16:30-17:00	PLE02-02	Undifferentiated Acute Leukemia	Daniel Boyer (Michigan, USA)
17:00-17:30		Clinical Cytometry Best Original Paper Award 2023-2024	Auditorium Mallorca
17:30-18:30		Welcome Reception	Palma Room

THURSDAY 26 SEPTEMBER 2024

99:30:103NameName of timmunophenotype in Myelodysplastic SyndromesMuditorium Mallora09:30:103PAR010To be confirmedWolfgang Kern (München, DEJ10:30:103PAR020Cancer-Monitoring of cancer-specific immunitySala Menorca09:30:1030PAR020Cancer-Monitoring of cancer-specific immunitySala Menorca09:30:1030PAR020Cancer-specific immunomotioringWillem(in Hold) (Nijmegen, NJ)09:30:1030PAR020Cancer-specific immunomotioringWillem(in Hold)09:30:1030PAR020Cancer-specific immunomotioringWillem(in Hold)10:30:1045VCaffee break, Exhibition, PastersExhibition area11:51:143IPO0ESCC4/SC Loint SessionAuditorium Mallorce11:51:145PIE030Generation of allogeneic CD122 CAR- teslis for AML treatment inspiranciesInes Zugastil (Barcelona, ES)12:51:245PIE030Generation of allogeneic CD122 CAR- teslis for AML treatment inspiranciesLuis Mource (Madrid, ES)12:51:245PIE030Generation of allogeneic CD122 CAR- teslis for AML treatment inspiranciesLuis Mource (Madrid, ES)12:51:245PIE030Generation of allogeneic CD122 CAR- teslis for AML treatment inspiranciesLuis Mource (Madrid, ES)12:51:245PIE0300Generation of allogeneic CD122 CAR- teslis for AML treatment inspiranciesLuis Mource (Madrid, ES)12:51:245PIE0300Generation of allogeneic CD122 CAR- teslis for AML treatment inspiranciesLuis Mource (Madrid, ES)12:51:245PIE040Selected Best Abstr				
10.00-10.30 PA8.0-20 Multicenter prospective evaluation of diagnostic potential of flow cytometric, averancies in myelodysplastic syndromes by the ELN IMDS flow working group Wolfgang Kern (Minchen, DE) 0.8A 09.30.1000 PA802 Cancer- Monitoring of cancer-specific immunity Sale Menorca 09.30.1000 PA802.02 Cancer- Monitoring of Cancer-specific immunity Willemin Hobo (Nijmegen, Ni) Speaker to be confirmed inhibition Across Cancer Types 10.00.1030 PA802.02 Caffee break, Exhibition, Posters Kultorium Mallorca 11.45-1145 IPO2 ESCCA/SCI Joint Session Malganotes Audiorium Mallorca 11.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Ines Zugasti (Barcelona, ES) Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-	09:30-10:45	PAR01	The role of immunophenotype in Myelodysplastic Syndromes	Auditorium Mallorca
10.00-10.30 PA8.0-20 Multicenter prospective evaluation of diagnostic potential of flow cytometric, averancies in myelodysplastic syndromes by the ELN IMDS flow working group Wolfgang Kern (Minchen, DE) 0.8A 09.30.1000 PA802 Cancer- Monitoring of cancer-specific immunity Sale Menorca 09.30.1000 PA802.02 Cancer- Monitoring of Cancer-specific immunity Willemin Hobo (Nijmegen, Ni) Speaker to be confirmed inhibition Across Cancer Types 10.00.1030 PA802.02 Caffee break, Exhibition, Posters Kultorium Mallorca 11.45-1145 IPO2 ESCCA/SCI Joint Session Malganotes Audiorium Mallorca 11.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Ines Zugasti (Barcelona, ES) Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-1245 PL830 Generation of allogeneic CD123 CAR-T cells for AML treatment Imaganotes Lui Avarce (Madrid, ES) 12.45-	09:30-10:00	PAR01-01	To be confirmed	
10:30-10:45Q&A10:30-10:45Q&A10:30-10:40PAR02Cancer - Monitoring of cancer - specific immunotySala Menorca10:30-10:40PAR02-02Cancer - specific immunomonitoring Immuno Call Profiling of Peripheral Blood as Signature for Response During CheckpointWillemijn Hobo (Nijmegen, NL) Speaker to be confirmed Imbibition Across Cancer Types10:30-10:45QCaffee break, Exhibition, PostersExhibition area11:51:13:45PP02ESCCA/SIC Joint Session Ralle of FCM in evaluating novel immunotherapy strategies for hematological malignanciesAudiorium Mallorca Response During Checkpoint11:45:12:15PE03Cancer - specific immuno Presentation 2Exclusion Ralle of FCM in evaluating novel immunotherapy strategies for hematological malignanciesLunch break, Exhibition, PostersExhibition area11:45:12:15PE03Cancer - specific immuno Rolle Presentation 2Exhibition areaExhibition area12:45:14:15VE03Callected Best Abstract presentation 1 (pre-registation required, max. 20 places)Exhibition area12:45:14:15PE04Selected Best Abstract presentation 3Auditorium Mallorca11:45:14:30PE040Selected Best Abstract presentation 3Auditorium Mallorca11:45:14:30PE0403Selected Best Abstract				Wolfgang Kern (München, DE)
93-30-04.00PAR02Cancer - Monitoring of cancespecific immunitySala Menorca093-01-030PAR02-01Cancer-specific immunomonitoring timbibition Across Cancer TypesWillemijn Hobo (Nijmegen, NL) speaker to be confirmed inhibition Across Cancer Types0130-01-035PAR02-02Cancer-specific immunomonitoring tombibition Across Cancer TypesExhibition across0130-01-035Caffee break, Exhibition, PostersExhibition acrossExhibition across1135-1145PE02ESCCA'SC Industrial Partner Presentation 2Additorium Mallorca1135-1215PIE03-00Eneration of allogeneic CD123 CAR-T cells for AML treatment tommune memory in vivoInes Zugasti (Barcelona, ES) tus Álværez (Madrid, ES)1245-1215PIE03-00Eneration of allogeneic CD123 CAR-T cells for AML treatment tommune memory in vivoInes Zugasti (Barcelona, ES) tus Álværez (Madrid, ES)1245-1215PIE03-00Eneration of allogeneic CD123 CAR-T cells for AML treatment tommune memory in vivoInes Zugasti (Barcelona, ES) tus Álværez (Madrid, ES)1245-1215PIE03-00Elected Best Abstract T cell streatment torre registration required; max: 20 places)Additorium Mallorca1415-1430PIE04-00Selected Best Abstract presentation 1 (pre-registration required; max: 20 places)Additorium Mallorca1415-1431PIE04-00Selected Best Abstract presentation 3 elected Best Abstract presentation 3Additorium Mallorca1415-1430PIE04-00Selected Best Abstract presentation 4Additorium Mallorca1415-1430PIE04-00Selected Best Abstract presentatio			aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group	
930-1020 930-1020PAR02-02 PAR02-02Cancer-specific immunomonitoring or immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer TypesWilemijn Hobo (Nijmegen, NL) Speaker to be confirmed Inhibition Across Cancer Types1030-1045O&AO&AExhibition Across Cancer Types1030-1045Coffee break, Exhibition, PostersExhibition area1115-1145PP02ESCCA Industrial Partner Presentation 2Auditorium Mallorca malignancies1145-1245PL030ESCCA/SIC Joint Session Role of FCM in evaluating novel Immunotherapy strategies for hematological malignanciesAuditorium Mallorca 	10:30-10:45		Q&A	
930-1020 930-1020PAR02-02 PAR02-02Cancer-specific immunomonitoring or immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer TypesWilemijn Hobo (Nijmegen, NL) Speaker to be confirmed Inhibition Across Cancer Types1030-1045O&AO&AExhibition Across Cancer Types1030-1045Coffee break, Exhibition, PostersExhibition area1115-1145PP02ESCCA Industrial Partner Presentation 2Auditorium Mallorca malignancies1145-1245PL030ESCCA/SIC Joint Session Role of FCM in evaluating novel Immunotherapy strategies for hematological malignanciesAuditorium Mallorca (Auditor, ES)1145-1245PL030- Promote Immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)1245-14-15Cunch break, Exhibition, PostersExhibition area1245-14-15Lunch break, Exhibition, PostersExhibition area1415-1430PL040Selected Best Abstract presentation 1 (pre-registration required; maz. 20 places)Auditorium Mallorca1415-1431PL040Selected Best Abstract presentation 2 (selected Best Abstract presentation 3 (sole 1-Abstract presentation 4Auditorium Mallorca1515-1545PP03ESCCA Industrial Partner Presentation 3 (sole 1-Abstract presentation 4Auditorium Mallorca1515-1545PP03ESCCA Industrial Partner Presentation 3 (sole 1-Abstract presentation 3 (sole 1-Abstract presentation 4Auditorium Mallorca1515-1545PP03Selected Best Abstract presentation 3 (sole 1-Abstract presentation 4Auditorium Mallorca <td>09:30-10:45</td> <td>PAR02</td> <td>Cancer - Monitoring of cancer-specific immunity</td> <td>Sala Menorca</td>	09:30-10:45	PAR02	Cancer - Monitoring of cancer-specific immunity	Sala Menorca
10:00-10:30PAR02-20Immune Cell Profiling of Peripheral Blood as Signature for Response During CheckpointSpeaker to be confirmed inhibition Across Cancer Types10:30-10:45OO&AExhibition Across Cancer Types10:30-10:45VCoffee break, Exhibition, PostersExhibition area11:15-11:45PP02ESCCA/SIC Joint Session Role of FCM in evaluating novel immunotherapy strategies for hematological malignanciesAuditorium Mallorca hole of FCM in evaluating novel immunotherapy strategies for hematological malignanciesMultionum Mallorca hole of FCM in evaluating novel immunotherapy strategies for hematological promote immune memory in vivo in Societ of FCM in evaluating novel immunotherapy strategies for hematological promote immune memory in vivo in Societ of PAROF POROFAuditorium Mallorca hole Societ of Barce Achibition, Posters12:45-14:15VGeneration of allogeneic CD123 CAR-T cells for AML treatment promote immunotherapy strategies control multiple myeloma and promote immunotherapy strategies for hematological promote immunotherapy strategies for hemato	05.00 10.45			
Inhibition Across Cancer TypesInhibition Across Cancer Types10:30-10:45OBA10:45-12:15Coffee break, Exhibition, PostersExhibition area11:15-11:45PP02ESCCA Industrial Partner Presentation 2Auditorium Mallorca11:45-12:15PL030ESCCA/SIC Joint Session noloci of FCM in evaluating novel immunotherapy strategies for hematological malignanciesAuditorium Mallorca11:45-12:15PL030EscCa/SIC Joint Session noloci of allogeneic CD123 CAR-T cells for AML treatment promote immune memory in vivoEscJugasti (Barcelona, ES)12:45-14:15VLuch break, Exhibition, PostersExhibition area12:45-14:15VNovarits Corporate Satellite Round Table Discussion on PNH (pre-registration required; max. 20 places)Exhibition area14:15-13:16PL040Selected Best Abstract presentation 1 Selected Best Abstract presentation 2 Selected Best Abstract presentation 2 Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:45:16:15PA030 Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:45:16:15PA0300 Selected Best Abstract presentation 3 Selected Best Abstract pres	09:30-10:00	PAR02-01	Cancer-specific immunomonitoring	Willemijn Hobo (Nijmegen, NL)
1030-1045 08A 1045-11:25 Coffee break, Exhibition, Posters Exhibition area 11115-1145 PP02 ESCCA Industrial Partner Presentation 2 1145-12:37 Reloo Reloo for Min evaluating novel immunotherapy strategies for hematological malignancies Addrorium Mallorca 1145-12:15 PL030 Generation of allogeneic CD123 CAR-T cells for AML treatment Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo Ines Zugasti (Barcelona, ES) 12:45-14:15 V Generation of allogeneic CD123 CAR-T cells for AML treatment Engineered T cell secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo Ines Zugasti (Barcelona, ES) 12:45-14:15 V Rozortis Corporate Satellite Round Table Discussion on PNH Exhibition area 14:45-14:30 PL040 Selected Best Abstract presentation 1 Selected Best Abstract presentation 2 14:45-14:31 PL0400 Selected Best Abstract presentation 3 Selected Best Abstract presentation 3 15:45-16:15 C Grife break, Exhibition, Posters Audiorium Mallorca 15:45-16:15 C Grife break, Exhibition, Posters Exhibition area 16:45-16:15 Coffee break, Exhibition, Posters Scade area Audio	10:00-10:30	PAR02-02		Speaker to be confirmed
1045-11:15 Coffee break, Exhibition, Posters Enhibition area 1115-11:16 IPP00 ECCA Industrial Partner Presentation 2 1145-12:16 RLE03 SECA/SIC Joint Session Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies for hematological Role of FCM in evaluating novel immunotherapy strategies control multiple myeloma and Role of FCM in evaluating novel immunotherapy strategies control multiple myeloma Role of FCM in evaluating novel immunotherapy strategies control multiple myeloma Role of FCM in evaluating novel immunotherapy strategies control multiple myeloma Role of Role of Ro	10.20 10.45			
11:15-11:45IPPO2ESCCA Industrial Partner Presentation 211:45-12:45PLE03ESCCA/SIC Joint Session malignanciesAuditorium Mallorca malignancies11:45-12:15PLE03-00Generation of allogeneic CD123 CAR-T cells for AML treatment Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)12:45-14:15CGeneration of allogeneic CD123 CAR-T cells for AML treatment Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)12:45-14:15CKororate Satellite Round Table Discussion on PNH (pre-registration reguired; max. 20 places)to be confirmed14:15-14:30PLE04-00Selected Best Abstract 1Auditorium Mallorca14:15-14:30PLE04-00Selected Best Abstract presentation 1 Selected Best Abstract presentation 3 Selected Best Abstract presentation 315:15:15:45PP03Caffee break, Exhibition, PostersAuditorium Mallorca16:15:16:45PAR030Classification of T-CLPD based on expert-independent FCM tools SCCA T-CLPD case series QRAAuditorium Mallorca16:15:16:45PAR040Classification of T-CLPD based on expert-independent FCM tools ScCA T-CLPD case seri	10.30-10.45		Uan .	
11:45-12:45PLE03ESCCA/SIC Joint Session Relice of FCM in evaluating novel immunotherapy strategies for hematological malignanciesAuditorium Mallorca Ines Zugasti (Barcelona, ES) Luis Alvarez (Madrid, ES)11:45-12:15PLE03-02Generation of allogeneic CD123 CAR-T cells for AML treatment Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)12:45-14:15VLunch break, Exhibition, PostersExhibition area12:45-14:15VNovartis Corporate Satellite Round Table Discussion on PNH (pre-registration required, max. 20 places)to be confirmed14:15-15:15PLE04Selected Best Abstracts 1Auditorium Mallorca14:15-14:30PLE04-03Selected Best Abstract presentation 1 14:30-14:45Selected Best Abstract presentation 1 15:00-15:15PLE04-0415:15-15:45IPP03ESCCA Industrial Partner Presentation 3 15:00-15:15Auditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM tools 15:45-17:15Julia Almeida (Salamanca, ES) Speaker to be confirmed 208A16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy 08ARenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Nasc cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughent Pregnancy 08AMichael Eikmans (Leiden, NL)	10:45-11:15		Coffee break, Exhibition, Posters	Exhibition area
11:45-12:45PLE03ESCCA/SIC Joint Session Relice of FCM in evaluating novel immunotherapy strategies for hematological malignanciesAuditorium Mallorca Ines Zugasti (Barcelona, ES) Luis Alvarez (Madrid, ES)11:45-12:15PLE03-02Generation of allogeneic CD123 CAR-T cells for AML treatment Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)12:45-14:15VLunch break, Exhibition, PostersExhibition area12:45-14:15VNovartis Corporate Satellite Round Table Discussion on PNH (pre-registration required, max. 20 places)to be confirmed14:15-15:15PLE04Selected Best Abstracts 1Auditorium Mallorca14:15-14:30PLE04-03Selected Best Abstract presentation 1 14:30-14:45Selected Best Abstract presentation 1 15:00-15:15PLE04-0415:15-15:45IPP03ESCCA Industrial Partner Presentation 3 15:00-15:15Auditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM tools 15:45-17:15Julia Almeida (Salamanca, ES) Speaker to be confirmed 208A16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy 08ARenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Nasc cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughent Pregnancy 08AMichael Eikmans (Leiden, NL)	11.15 11.45	10000	FCCCA Industrial Davis as Descentration 2	
Role of FCM in evaluating novel immunotherapy strategies for hematological malignancies 11.45-12.15 PLE03-00 Generation of allogeneic CD123 CAR-T cells for AML treatment Ingineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo Ines Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES) 12.45-14:15 V Lunch break, Exhibition, Posters Exhibition area 12.45-14:15 V Novartis Corporate Satellite Round Table Discussion on PNH (pre-registration required; mox. 20 places) Auditorium Mallorca 14.15-14:30 PLE04 Selected Best Abstracts 1 Auditorium Mallorca 14.15-14:30 PLE040 Selected Best Abstract presentation 1 Selected Best Abstract presentation 2 14.30-14:45 PLE0404 Selected Best Abstract presentation 3 Selected Best Abstract presentation 3 15:00-15:15 PP03 ESCCA Industrial Partner Presentation 3 Auditorium Mallorca 16:15-16:45 PAR03 Classification of T-CLPD based on expert-independent FCM tools Selected (Sat Ambring, NL) 16:15-16:45 PAR04 Classification of T-CLPD based on expert-independent FCM tools Sela Menorca 16:15-16:45 PAR040 Classification of T-CLPD based on expert-independent FCM tools Sela Menorca 16:15-16:45	11:15-11:45	IPP02	ESCCA Industrial Partner Presentation 2	
nalignanciesmalignancies11.45-12.15PLE03-01Generation of allogeneic CD123 CAR-T cells for AML treatment Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)12.45-14:15 <i>Lunch break, Exhibition, Posters</i> Exhibition area12.45-14:15Novartis Corporate Satellite Round Table Discussion on PNH (pre-registration required; max. 20 places)to be confirmed14.15-14:30PLE04Selected Best Abstracts 1Auditorium Mallorca14.15-14:30PLE04-01Selected Best Abstract presentation 1 Selected Best Abstract presentation 2 Selected Best Abstract presentation 2 Selected Best Abstract presentation 3Auditorium Mallorca15.15-15:45PLE04-04Selected Best Abstract presentation 3Auditorium Mallorca15.45-16:15Coffee break, Exhibition, PostersExhibition area16.15-16:45PAR03Cassification of T-CLIP Dased on expert-independent FCM tools (RAA)Julia Almeida (Salamanca, ES) Speaker to be confirmed (RAA)16.15-16:45PAR04The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy (RAA)Renate van der Molen (Nijmegen, NL)16.15-16:45PAR040The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16.15-16:45PAR040The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16.15-16:45PAR040The Promises of Natural Killer Cell Therapy in Endometriosi	11:45-12:45	PLE03	ESCCA/SIC Joint Session	Auditorium Mallorca
11.45-12.15PLE03-01Generation of allogeneic CD123 CAR-T cells for AML treatment promote immune memory in vivoInes Zugasti (Barcelona, ES) Luis Álvarez (Madrid, ES)12.45-14:15Lunch break, Exhibition, PostersExhibition area12.45-14:15Lunch break, Exhibition, PostersExhibition area12.45-14:15Lunch break, Exhibition, PostersExhibition area12.45-14:15Lunch break, Exhibition, PostersExhibition area12.45-14:15Novartis Corporate Satellite Round Table Discussion on PNH (pre-registration required; max. 20 places)to be confirmed14:15-14:30PLE04Selected Best Abstracts 1Auditorium Mallorca14:35-14:45PLE04-01Selected Best Abstract presentation 1 14:30-14:45Selected Best Abstract presentation 2 15:45-16:1515:15-15:45IPP03ESCCA Industrial Partner Presentation 3 15:00-15:15Auditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03-01 Q&AClassification of T-CLPD based on expert-independent FCM tools Q&AJulia Almeida (Salamanca, ES) Speaker to be confirmed16:15-16:45PAR03-01 Q&AThe Promises of Natural Killer Cell Therapy in Endometriosis NURenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-01 PR04-02The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy Q&ARenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-01 PR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy Q&AMichael Eikmans (Leiden, NL) <b< td=""><td></td><td></td><td></td><td></td></b<>				
12.15-12.45PLE03-02Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoLuis Álvarez (Madrid, ES)12.45-1415Lunch break, Exhibition, PostersExhibition area12.45-1415Novaris Corporate Satellite Round Table Discussion on PNH (<i>rer-registration required; max. 20 places</i>)to be confirmed14.15-1515PLE04Selected Best Abstract 1Auditorium Mallorca14.15-143PLE0403Selected Best Abstract presentation 1selected Best Abstract presentation 214.15-143PLE0404Selected Best Abstract presentation 1Selected Best Abstract presentation 214.15-1430PLE0405Selected Best Abstract presentation 3Selected Best Abstract presentation 315.09-1515PLE0405Selected Best Abstract presentation 4Auditorium Mallorca15.45-1615Long Coffee break, Exhibition, PostersExhibition area16.15-1624PAR030Reproductive ImmunologyAuditorium Mallorca16.15-1635PAR030Classification of T-CLID based on expert-independent FCM tools 0&ASelected Sest Abstract Presentation 316.15-1645PAR040Reproductive ImmunologySala Menorca16.15-1645PAR040The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy 0&ASala Menorca16.15-1645PAR0400Mass cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy 0&AMass cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy 0&A			malignancies	
12.15-12.45PLE03-02Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivoLuis Álvarez (Madrid, ES)12.45-1415Lunch break, Exhibition, PostersExhibition area12.45-1415Novaris Corporate Satellite Round Table Discussion on PNH (<i>rer-registration required; max. 20 places</i>)to be confirmed14.15-1515PLE04Selected Best Abstract 1Auditorium Mallorca14.15-143PLE0403Selected Best Abstract presentation 1selected Best Abstract presentation 214.15-143PLE0404Selected Best Abstract presentation 1Selected Best Abstract presentation 214.15-1430PLE0405Selected Best Abstract presentation 3Selected Best Abstract presentation 315.09-1515PLE0405Selected Best Abstract presentation 4Auditorium Mallorca15.45-1615Long Coffee break, Exhibition, PostersExhibition area16.15-1624PAR030Reproductive ImmunologyAuditorium Mallorca16.15-1635PAR030Classification of T-CLID based on expert-independent FCM tools 0&ASelected Sest Abstract Presentation 316.15-1645PAR040Reproductive ImmunologySala Menorca16.15-1645PAR040The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy 0&ASala Menorca16.15-1645PAR0400Mass cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy 0&AMass cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy 0&A	11.45-12.15	PLE03-01	Generation of allogeneic CD123 CAR-T cells for AML treatment	Ines Zugasti (Barcelona, ES)
12:45:14:15Lunch break, Exhibition, PostersExhibition area12:45:14:15Lunch break, Exhibition, PostersExhibition area12:45:14:15Novartis Corporate Satellite Round Table Discussion on PNH (mer-registration required; max. 20 places)to be confirmed14:15:14:30PLE04-01Selected Best Abstract 1Auditorium Mallorca14:15:14:30PLE04-01Selected Best Abstract presentation 1Auditorium Mallorca14:35:14:30PLE04-02Selected Best Abstract presentation 2Selected Best Abstract presentation 315:00:15:15PLE04-03Selected Best Abstract presentation 3Auditorium Mallorca15:15:16:45Coffee break, Exhibition, PostersExhibition area16:15:16:45Coffee break, Exhibition, PostersExhibition area16:15:16:45PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15:16:45PAR04Reproductive ImmunologySala Menorca16:15:16:45PAR04Reproductive ImmunologySala Menorca16:15:16:45PAR04The Promises of Natural Killer Cell Therapy in EndometriosisRenate van der Molen (Nijmegen NL)16:15:16:45PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Elkmans (Leiden, NL)16:15:16:45PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface ThroughoutMichael Elkmans (Leiden, NL)16:15:16:45PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface ThroughoutMichael Elkmans (Leiden, NL) <td></td> <td></td> <td></td> <td></td>				
12:45-14:15Novartis Corporate Satellite Round Table Discussion on PNH (pre-registration required; max. 20 places)to be confirmed14:15-14:10PLE04-01Selected Best Abstracts 1Auditorium Mallorca14:15-14:30PLE04-02Selected Best Abstract presentation 1 (Selected Best Abstract presentation 2 Selected Best Abstract presentation 3 (Soci-15:15)Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:15-15:47IPP03ESCCA Industrial Partner Presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-00 (Cassification of T-CLPD based on expert-independent FCM tools) (Q&AJulia Almeida (Salamanca, ES) Speaker to be confirmed)16:15-16:45PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy Q&ARenate van der Molen (Nijmegen, NL)16:15-16:45PAR04-02Kase Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy Q&AKase Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy17:15-17:50PAR04-02Q&ASectometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy16:15-16:45PAR04-02Res Cytometry and the Dynamic C				
12:45-14:15Novartis Corporate Satellite Round Table Discussion on PNH (pre-registration required; max. 20 places)to be confirmed14:15-14:10PLE04-01Selected Best Abstracts 1Auditorium Mallorca14:15-14:30PLE04-02Selected Best Abstract presentation 1 (Selected Best Abstract presentation 2 Selected Best Abstract presentation 3 (Soci-15:15)Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:15-15:47IPP03ESCCA Industrial Partner Presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-00 (Cassification of T-CLPD based on expert-independent FCM tools) (Q&AJulia Almeida (Salamanca, ES) Speaker to be confirmed)16:15-16:45PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy Q&ARenate van der Molen (Nijmegen, NL)16:15-16:45PAR04-02Kase Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy Q&AKase Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy17:15-17:50PAR04-02Q&ASectometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy16:15-16:45PAR04-02Res Cytometry and the Dynamic C	12 15 11 15			
Interpretation required; max. 20 places) Interpretation Auditorium Maillorca Interpretation Selected Best Abstracts 1 Auditorium Maillorca Interpretation Selected Best Abstract presentation 1 Selected Best Abstract presentation 2 Interpretation Selected Best Abstract presentation 2 Selected Best Abstract presentation 2 Interpretation Selected Best Abstract presentation 3 Selected Best Abstract presentation 3 Interpretation Selected Best Abstract presentation 4 Auditorium Mailorca Interpretation Selected Best Abstract presentation 3 Selected Best Abstract presentation 4 Interpretation Selected Best Abstract presentation 4 Auditorium Mailorca Interpretation Selected Best Abstract presentation 5 Auditorium Mailorca Interpretation Selected Best Abstract presentation 6 Auditorium Mailorca Interpretation Reservertation 7 Selected Best Abstract presentation 4 Auditorium Mailorca	12:45-14:15			
14:15-15:15PLE04Selected Best Abstract 1Auditorium Mallorca14:15-14:30PLE04-01Selected Best Abstract presentation 1114:30-14:45PLE04-02Selected Best Abstract presentation 2114:45-15:00PLE04-03Selected Best Abstract presentation 3115:01-15:15PLE04-04Selected Best Abstract presentation 4115:15-15:45IPP03ESCCA Industrial Partner Presentation 3Auditorium Mallorca15:45-16:15Caffee break, Exhibition, PostersExhibition area16:15-16:45PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-02Classification of T-CLPD based on expert-independent FCM tools 0&AJulia Almeida (Salamanca, ES) Speaker to be confirmed16:00-17:15PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy	12:45-14:15		•	to be confirmed
14:15-14:30PLE04-01Selected Best Abstract presentation 114:30-14:45PLE04-02Selected Best Abstract presentation 214:45-15:00PLE04-03Selected Best Abstract presentation 315:00-15:15PLE04-04Selected Best Abstract presentation 415:15-15:45IPP03ESCCA Industrial Partner Presentation 315:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM tools ESCCA T-CLPD case series Q&AJulia Almeida (Salamanca, ES) Speaker to be confirmed16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Q&AMass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy17:15-17:30Q&AQ&A			(pre-registration required, max. 20 places)	
14:30-14:45PLE04-03Selected Best Abstract presentation 2 Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:15:15:15:15:15:15:15:15:15:15:15:15:1	14:15-15:15	PLE04	Selected Best Abstracts 1	Auditorium Mallorca
14:30-14:45PLE04-03Selected Best Abstract presentation 2 Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:15:15:15:15:15:15:15:15:15:15:15:15:1				
14:45-15:00PLE04-03Selected Best Abstract presentation 3 Selected Best Abstract presentation 4Auditorium Mallorca15:15-15:45IPP03ESCCA Industrial Partner Presentation 3 Coffee break, Exhibition, PostersAuditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-17:20PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM tools Speaker to be confirmedJulia Almeida (Salamanca, ES) Speaker to be confirmed16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy Q&ASelected ImmunologySala Menorca16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy Q&AMichael Eikmans (Leiden, NL) Pregnancy Q&A	14:15-14:30	PLE04-01	Selected Best Abstract presentation 1	
15:00-15:15 PLE04-04 Selected Best Abstract presentation 4 15:15-15:45 IPPO3 ESCCA Industrial Partner Presentation 3 Auditorium Mallorca 15:15-16:15 Coffee break, Exhibition, Posters Exhibition area 16:15-17:30 PAR03 New FCM-based approach of T-cell chronic neoplasms Auditorium Mallorca 16:15-16:45 PAR03-02 Classification of T-CLPD based on expert-independent FCM tools Julia Almeida (Salamanca, ES) 16:05-17:15 PAR04-02 Reproductive Immunology Selected Immunology Selected Immunology 16:15-16:45 PAR04-0 Reproductive Immunology Renate van der Molen (Nijmegen, NL) 16:15-16:45 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Renate van der Molen (Nijmegen, NL) 16:45-17:15 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL) 17:15-17:30 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL) 17:15-17:30 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL)	14:30-14:45	PLE04-02	Selected Best Abstract presentation 2	
15:15-15:45IPPO3ESCCA Industrial Partner Presentation 3Auditorium Mallorca15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-17:30PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-02Classification of T-CLPD based on expert-independent FCM tools ESCCA T-CLPD case series Q&AJulia Almeida (Salamanca, ES) Speaker to be confirmed16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-02The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL) Pregnancy17:15-17:30Q&AQ&AMichael Eikmans (Leiden, NL)				
15:45-16:15Coffee break, Exhibition, PostersExhibition area16:15-16:45PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM tools ESCCA T-CLPD case series Q&AJulia Almeida (Salamanca, ES) Speaker to be confirmed16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis Pregnancy Q&ARenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy Q&AMichael Eikmans (Leiden, NL)	15:00-15:15	PLE04-04	Selected Best Abstract presentation 4	
16:15-17:30PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM toolsJulia Almeida (Salamanca, ES)16:45-17:15PAR03-02ESCCA T-CLPD case series Q&ASpeaker to be confirmed16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL)17:15-17:30Q&AQ&AMichael Eikmans (Leiden, NL)	15:15-15:45	IPP03	ESCCA Industrial Partner Presentation 3	Auditorium Mallorca
16:15-17:30PAR03New FCM-based approach of T-cell chronic neoplasmsAuditorium Mallorca16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM toolsJulia Almeida (Salamanca, ES)16:45-17:15PAR03-02ESCCA T-CLPD case series Q&ASpeaker to be confirmed16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL)17:15-17:30Q&AQ&AMichael Eikmans (Leiden, NL)				
16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM toolsJulia Almeida (Salamanca, ES)16:45-17:15PAR03-02ESCCA T-CLPD case series Q&ASpeaker to be confirmed17:15-17:30PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL)17:15-17:30Q&AQ&AMichael Eikmans (Leiden, NL)	15:45-16:15		Coffee break, Exhibition, Posters	Exhibition area
16:15-16:45PAR03-01Classification of T-CLPD based on expert-independent FCM toolsJulia Almeida (Salamanca, ES)16:45-17:15PAR03-02ESCCA T-CLPD case series Q&ASpeaker to be confirmed17:15-17:30PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL)17:15-17:30Q&AQ&AMichael Eikmans (Leiden, NL)				
16:45-17:15 17:15-17:30PAR03-02 C&AESCCA T-CLPD case series Q&ASpeaker to be confirmed16:45-17:15 16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01 The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02 Q&AMass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL)17:15-17:30Q&AMichael Eikmans (Leiden, NL)Michael Eikmans (Leiden, NL)	16:15-17:30	PAR03	New FCM-based approach of T-cell chronic neoplasms	Auditorium Mallorca
16:45-17:15 17:15-17:30PAR03-02 C&AESCCA T-CLPD case series Q&ASpeaker to be confirmed16:45-17:15 16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01 The Promises of Natural Killer Cell Therapy in Endometriosis PregnancyRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02 Q&AMass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout PregnancyMichael Eikmans (Leiden, NL)17:15-17:30Q&AMichael Eikmans (Leiden, NL)Michael Eikmans (Leiden, NL)	16:15-16:45	PAR03-01	Classification of T-CLPD based on expert-independent FCM tools	Julia Almeida (Salamanca. ES)
17:15-17:30Q&A16:00-17:15PAR04Reproductive ImmunologySala Menorca16:15-16:45PAR04-01The Promises of Natural Killer Cell Therapy in EndometriosisRenate van der Molen (Nijmegen, NL)16:45-17:15PAR04-02Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface ThroughoutMichael Eikmans (Leiden, NL)17:15-17:30Q&A				
16:15-16:45 PAR04-01 The Promises of Natural Killer Cell Therapy in Endometriosis Renate van der Molen (Nijmegen, NL) 16:45-17:15 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL) 17:15-17:30 Q&A	17:15-17:30		Q&A	
16:15-16:45 PAR04-01 The Promises of Natural Killer Cell Therapy in Endometriosis Renate van der Molen (Nijmegen, NL) 16:45-17:15 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL) 17:15-17:30 Q&A				
16:45-17:15 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL) 17:15-17:30 Q&A	16:00-17:15	PAR04	Reproductive Immunology	Sala Menorca
16:45-17:15 PAR04-02 Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Michael Eikmans (Leiden, NL) 17:15-17:30 Q&A	16.15-16.45	PAR04-01	The Promises of Natural Killer Cell Therany in Endometricsis	Renate van der Molen (Niimegen
Pregnancy 17:15-17:30 Q&A	-0.13 10.43	. ,	e	
17:15-17:30 Q&A	16:45-17:15	PAR04-02	Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout	Michael Eikmans (Leiden, NL)
			Pregnancy	
17:40-18:45 ESCCA General Assembly Sala Menorca	17:15-17:30		Q&A	
	17:40-18:45		ESCCA General Assembly	Sala Menorca

FRIDAY 27 SEPTEMBER 2024

	54565		
09:30-10:45	PAR05	MRD in the modern treatment of leukemia	Auditorium Mallorca
09:30-10:00	PAR05-01	Advancing innovation and standardization in FLOW-MRD detection for pediatric AML	Margarita Maurer-Granofzsky (Vienna, AT)
10:00-10:30 10:30-10:45	PAR05-02	Advanced MRD analysis with NGS/MFC Q&A	Christiaan Vonk (Rotterdam, NL)
09:30-10:45	PAR06	Basic and practical immunology	Sala Menorca
09:30-10:00	PAR06-01	The effect of CMV infection and HLA-type on peripheral blood lymphocyte reference values	Alejandra Pera (Córdoba, ES)
10:00-10:30	PAR06-02	Standardization of Workflow and Flow Cytometry Panels for Quantitative Expression Profiling of Surface Antigens on Blood Leukocyte Subsets: An HCDM CDMaps Initiative	Tomas Kalina (Prague, CZ)
10:30-10:45		Q&A	
10:45-11:15		Coffee break, Exhibition, Posters	Exhibition area
11:15-12:00	PLE05	Interactive case presentations in Hemato-Oncology	Auditorium Mallorca
11:15-12:00	PLE05-01	Lymphoproliferative diseases	Sindhu Cherian (Washington, USA)
12:00-12:30	IPP04	ESCCA Industrial Partner Presentation 4	Mallorca Auditorium
12:30-13:45		Lunch break, Exhibition, Posters	Exhibition area
13:45-14:15	PLE06	ESCCA/ESID joint session	Auditorium Mallorca
13:45-14:15	PLE06-01	FC applications in HLH	Yenan Bryceson (Stockholm, SE)
14:15-15:15	PLE07	Selected Best Abstracts 2	Auditorium Mallorca
14.15 14.20	DI 507 01		
14:15-14:30 14:30-14:45		Selected Best Abstract presentaton 5 Selected Best Abstract presentaton 6	
14:45-15:00			
		Selected Best Abstract presentation 8	
15:15-15:30	CI 01	Corporate Lecture	Mallorca Auditorium
15.15-15.50	CLUI		
15:30-16:00		Coffee break, Exhibition, Posters	Exhibition area
16:00-17:15	PAR07	Artificial Intelligence and quality control in flow-cytometric data	Auditorium Mallorca
16:00-16:30	PAR07-01	Possibilities of AI for clinical cytometry data analysis	Yvan Saeys (Ghent, BE)
16:30-17:00	PAR07-02	Pre-processing, potential of automated methods for MRD detection	Sarha Bonte (Ghent, BE)
17:00-17:15		Q&A	
16:00-17:15	PAR08	Extracellular Vesicles	Sala Menorca
16:00-16:30	PAR08-01	Extracellular vesicles as potential biomarkers. Considerations for sample processing, analysis and sorting	Alfonso Blanco (Dublin, IE)
16:30-17:00	PAR08-02	Labeling extracellular vesicles for flow cytometry analyses	Paola Lanuti (Chieti, IT)
17:00-17:15		Q&A	
19:00-23:00		Conference Dinner at Son Termes Pre-registration required; a fee applies	

SATURDAY 28 SEPTEMBER 2024

09:30-10:45	PAR09	Focus on IVDR	Auditorium Mallorca
09:30-10:00	PAR09-01	LDT and IVDR: what's new?	Marie-Christine Béné (Nantes, FR)
10:00-10:30	PAR09-02	IVDR-compliant validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry	Orianne Wagner-Ballon (Créteil, FR)
10:30-10:45		Q&A	
09:30-10:45	PAR10	Clinical cytometry in transplantation	Sala Menorca
09:30-10:00	PAR10-01	NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma	Simon Mitchell (Brighton, UK)
10:00-10:30	PAR10-02	To be confirmed	
10:30-10:45		Q&A	
10:45-11:15		Coffee break, Exhibition, Posters	Exhibition area
11:15-11:45	PLE08	Keynote Lecture 2: CAR-NK cells	Auditorium Mallorca
11:15-11:45	PLE08-01	Off-the-shelf CD70-targeting CAR NK cells: Preclinical and early phase clinical updates	Sunil Acharya (Houston, USA)
11:45-12:45	PLE09	Hemato-Oncology: Interactive Case Presentation	Auditorium Mallorca
12:45-13:00	PLE10	ESCCA Awards session & Closure	Auditorium Mallorca
		Post Oral Procentation & Post Postor Awards	

Best Oral Presentation & Best Poster Awards ESCCA 2025 Closing Address